人工心脏之LVAD：国产陆续上市填补空白蓝海市场_31页_1mb

LVAD Market and Technology Analysis

Global Heart Failure Prevalence

Heart failure is a growing health issue with an increasing number of cases globally. In China, the prevalence is around 890 million people aged 35 years and older, with an annual new case count of approximately 297 million individuals aged 25 and above. Globally, estimates suggest about 6400 million people affected, and the trend is rising. Advanced heart failure often requires mechanical support, with left ventricular assist devices (LVADs) emerging as a key treatment.

Advanced Heart Failure Treatment

Guidelines recommend LVADs as a primary treatment for advanced heart failure, with options including cardiac transplantation and mechanical circulatory support. LVADs are especially effective for durable support, offering survival rates comparable to transplantation in some cases. In the U.S., LVAD usage has shifted towards destination therapy, with full magnetic levitation devices like the Abbott HeartMate III becoming dominant due to better outcomes and reduced complications.

LVAD Technology Evolution

LVAD technology has undergone three generations: pulsatile pumps, axial-flow pumps, and centrifugal designs with magnetic suspension. The most recent generation features fully magnetic levitation systems, which significantly improve survival by reducing blood clots and complications. For example, Abbott's HeartMate III has shown superior 5-year survival rates compared to older models, while Medtronic's HVAD was recently discontinued due to drawbacks like higher risks of neurological events.

Domestic Market in China

The Chinese market for LVADs was historically underserved until 2019, when four domestic companies—Yongrenxin Medical, Coreheart Medical, Tongxin Medical, and Aerospace Taixin—received approvals. As of 2021, LVAD use in China was around 11% of heart transplant transitions, up from nearly 0% in 2020, indicating slow but growing adoption. Clinical data suggests high survival rates for these devices, mirroring overseas standards.

Key Companies

Leading companies include Yongrenxin (EVAHEART), known for its first domestic approval and long-term support capability; Coreheart (Corheart 6), the lightest and smallest LVAD globally; Tongxin (Cifu), representing early domestic advancements; and Aerospace Taixin using hybrid suspension technology. Each offers competitive products with strong clinical performance.

Risks

Potential risks include slower-than-expected sales in the emerging market, increased competition if more firms enter, and downward pricing pressure due to high current costs, which could affect revenue and profitability.